Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CYP-5A1 CYP5-A1 CYP5A-1 CYP-2C5 2C3 P-450 5A-1 TXA-2 PGH-2 12(S)HHT 12SHHT LTB-4 BLT-2 Escherichia TXS
- Product Overview:
Thromboxane A synthase (TXAS), also known as cytochrome P450 (CYP) isoform CYP5A1, is the enzyme that catalyzes the isomerization of prostaglandin H2 (PGH2; Item No. 17020) into thromboxane A2 (TXA2), a vasoconstrictor and an inducer of platelet aggregation.{61821,61822} It also catalyzes the cleavage of PGH2 into malondialdehyde (MDA) and 12(S)-hydroxyheptadecatrienoic acid (12(S)-HHT; Item No. 34590), a leukotriene B4 (LTB4) receptor 2 (BLT2) agonist that also has a role in platelet aggregation.{61821} TXAS exists as a monomer and is composed of an N-terminal membrane anchor domain, a heme-binding catalytic residue, and several substrate-binding residues.{61823,61824,61825} It is expressed in numerous cells, including platelets, monocytes, and macrophages, as well as several tissues, and is localized to the endoplasmic reticulum.{61823} TXAS undergoes suicide inactivation during catalysis. Mice deficient in TXAS exhibit prolonged bleeding time and defective platelet aggregation.{61826} Cayman’s Thromboxane A Synthase (human, recombinant) protein can be used for enzyme activity assay and Western blot (WB) applications. To construct this protein, the N-terminal amino acids 1-29 of human CYP5A1 were removed and replaced with a hydrophilic sequence. The F-G loop of TXAS was modified using sequences from rabbit CYP2C5 and CYP2C3. The C-terminal of this protein contains 6x-His tag followed by a stop codon.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.